Pacific Bio (PACB) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Pacific Bio (PACB) Reports In-Line Q4 EPS

Piper Jaffray Downgrades Pacific Biosciences of California (PACB) to Neutral

February 4, 2016 6:37 AM EST

Piper Jaffray downgraded Pacific Biosciences of California (NASDAQ: PACB) from Overweight to Neutral with a price target of $11.00 (from $9.00).

Analyst William Quirk commented, "PacBio reported 4Q15 revenue of $36.3M, ~in line with the Street's $36.6M forecast. EPS of $(0.02) was also in line. PacBio... More